MARC details
| 000 -LEADER |
|---|
| fixed length control field |
08353cam a2200385 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
22064811 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
TH-BaNU |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20220916084946.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
220916s2022 nyua b 001 0 eng |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
|---|
| LC control number |
2021940388 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780826137425 |
| Qualifying information |
(paperback) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| Canceled/invalid ISBN |
9780826137432 |
| Qualifying information |
(ebook) |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
DLC |
| Language of cataloging |
eng |
| Description conventions |
rda |
| Transcribing agency |
DLC |
| 042 ## - AUTHENTICATION CODE |
|---|
| Authentication code |
pcc |
| 060 ## - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
|---|
| Classification number |
QZ266 |
| Item number |
B215 2022 |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Cancer immunotherapy principles and practice / |
| Statement of responsibility, etc. |
editors Lisa H. Butterfield, PhD (Vice President, Research and Development, Parker Institute for Cancer Immunotherapy, Adjunct Professor of Microbiology and Immunology, University of California San Francisco, San Francisco, California), Howard L. Kaufman, MD, FACS (Clinical Associate, Division of Surgical Oncology, Massachusetts, General Hospital, Harvard Medical School, Boston, Massachusetts), Francesco M. Marincola, MD (President and Chief Scientific Officer, Refuge Biotechnologies, Menlo Park, California) ; section editors Paolo A. Ascierto, MD, Raj K. Puri, MD, PhD. |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
2nd edition. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
New York, NY : |
| Name of producer, publisher, distributor, manufacturer |
Demos Medical, an imprint of Springer Publishing, |
| Date of production, publication, distribution, manufacture, or copyright notice |
[2022] |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xxxv, 941 pages : |
| Other physical details |
color illustrations ; |
| Dimensions |
29 cm |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
unmediated |
| Media type code |
n |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Carrier type code |
nc |
| Source |
rdacarrier |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Includes bibliographical references and index. |
| 505 ## - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
History of Cancer Immunotherapy --- Basic Principles of Tumor Immunology --- Introduction to Basic Sciences: The Caduceus of Cancer-Immune Responsiveness and Cancer Biology --- Genomic Determinants of Cancer Immune Response and Resistance --- Human Tumor Antigens Recognized by T Lymphocytes --- Structural and Functional Defects in HLA Class I Antigen Processing Machinery in Cancer Cells: Molecular Mechanisms and Clinical Relevance --- Systems Biology of T Cells --- Activation of CD4+ T Lymphocytes --- Regulation of Cell-Mediated Immunity: The Biology of Checkpoints and Regulatory T Cells --- B Cells in Solid Tumors: Their Role in Tumor Pathogenesis and Antitumor Immunity --- Functional Status of T Cells: Stemness Versus Terminal Differentiation --- The Innate Immune System: Macrophages and Neutrophils --- Natural Killer Cell Effector Mechanisms Against Solid Tumors and Leukemias and Their Exploitation in Immunotherapy --- Immunogenic Cell Death and Cancer --- Cancer Cell-Intrinsic Pathways of Immune Resistance --- Chemokines and Chemokine Receptors: Regulators of Tumor Immunity --- Role of the Tumor Microenvironment --- Cancer-Immune Exclusion: An Enigmatic Phenomenon --- Cancer Biomarkers: Tumor-Infiltrating T Cells, Programmed Death-Ligand 1, and Tumor Mutation Burden --- Role of the Microbiota in Carcinogenesis and Cancer Therapy --- Synthetic Biology for the Immunotherapy of Cancer --- Cancer Immunotherapy Targets and Classes --- Introduction to Principles of Cancer Immunotherapy --- Manipulating Innate Immune Pathways for Cancer Immunotherapy --- Cancer Vaccines: Considerations of Antigen, Formulation, and Delivery --- T Cell Modulatory Cytokines --- Non-Engineered Adoptive T Cell Therapy --- CAR T Cell Therapy --- Immunotherapy Based on Blocking Cell Inhibitory Pathways --- Agonistic Antibodies to Co-Stimulatory Molecules --- Immune Effects of Conventional Cancer Therapeutics Free --- Oncolytic Viruses --- Metabolism of Tumor Immunity --- Principles of Combination Immunotherapies --- Immune Function in Cancer Patients --- Introduction to Immune Function in Cancer Patients --- Tumor-Infiltrating Myeloid Cells in Cancer Progression and Therapy Response --- Intratumoral Gene Signatures and Host Genetic Variations Associated With Immune Responsiveness --- Impact of Somatic Mutations on the Local and Systemic Antitumor Immune Response --- Tumor Antigen Profiling --- Assessment of Antitumor Immunity in Blood and Lymph Nodes --- Regulatory T Cell Biology and Its Applications in Cancer Immunotherapy --- Systemic Measures of Immune Function in Cancer Patients: Other Suppressive Cellular Mechanisms --- Circulating Mediators of Tumor-Induced Immune Suppression --- Harnessing B Cells and Tertiary Lymphoid Structures for Antitumor Immunity --- Blood Transcriptomic Approaches to Cancer Immunotherapy --- Advances in Techniques for Immunotherapy Biomarker Analysis --- Predictive Biomarkers (Programmed Death Ligand 1 Expression, Microsatellite Instability, and Tumor Mutational Burden) for Response to Immune Checkpoint Inhibitors --- Tumor Microenvironment Metabolism as a Primordial Checkpoint in Antitumor T Cell Immunity --- Age-Related Immune Function Changes as They Relate to Cancer Immunotherapy --- Clinical Measures: Tumor Response Assessments, Pseudoprogression, and Immunometabolism --- Disease-Specific Treatments and Outcomes --- Introduction: General Approach to Cancer Immunotherapy—Lessons Learned From the Past Years --- Immunotherapy in Melanoma --- Other Cutaneous Tumors: Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Cutaneous Sarcomas --- Immunotherapy in Genitourinary Malignancies --- Immunotherapy in Gastrointestinal Malignancies --- Immunotherapy of Hepatocellular Carcinoma --- Immunotherapy for Gynecologic Malignancies --- Breast Cancer Immunotherapy --- Immunotherapy for Lung Cancer and Malignant Pleural Mesothelioma --- Head and Neck Cancer --- Immunotherapy of Hematologic Malignancies: Lymphomas, Leukemias, and Myeloma --- Brain Tumors --- Sarcomas --- Pediatric Cancers: Neuroblastoma --- Immunotherapy in Combination With Radiation Therapy --- Regulatory Aspects of the Biological Therapy of Cancer --- Regulatory Considerations for Therapeutic Cancer Vaccines --- A Regulatory Perspective on Cell Therapy for Cancer: Chemistry, Manufacturing and Control, Preclinical, and Clinical Considerations --- Gene Therapy-Based Immunotherapy Products for Human Clinical Trials: Chemistry, Manufacturing and Control, Preclinical, and Clinical Considerations: An FDA Perspective --- Combination Immunotherapies: Regulatory Considerations --- Regulatory Considerations for In Vitro Companion Diagnostic Devices |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
"The second edition of Cancer Immunotherapy Principles and Practice, from the Society of Immunotherapy of Cancer, has been thoroughly updated to reflect major advances in the field of immuno-oncology in recent years and remains the definitive resource for information on tumor immunology and cancer immunotherapy treatments. An essential reference for both novice and experienced cancer researchers, oncologists, and related practitioners alike, the book not only guides readers through the fundamental scientific principles of the field all the way to translational and practical clinical applications for treating and managing oncologic disease, but also provides a comprehensive understanding of the regulatory processes that support the safe and effective delivery of immunotherapy to patients with cancer. The expanded and updated second edition covers major topics and innovations that have shaped the rapid development of immunotherapy and its ascension into the standard of care as first-line treatment for a growing number of disease settings. New to this edition are chapters with deeper insight into our understanding of cancer genomics and determinants of response, immunogenic cell death, cancer and stromal cell-intrinsic pathways of immune resistance, cancer immune exclusion, adoptive cell therapy, metabolomics, tumor mutation burden, immunotherapy in combination with radiation therapy, synthetic biology, and more. Complete with detailed illustrations, tables, and key points for targeted reference, Cancer Immunotherapy Principles and Practice, Second Edition is the most comprehensive and authoritative resource for scientists and clinicians looking to expand their knowledge base of this dynamic field"-- |
| Assigning source |
Provided by publisher. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Cancer |
| General subdivision |
Immunotherapy. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Butterfield, Lisa H., |
| Relator term |
editor. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Kaufman, Howard L., |
| Relator term |
editor. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Marincola, Francesco M., |
| Relator term |
editor. |
| 850 ## - HOLDING INSTITUTION |
|---|
| Holding institution |
Kuakarun Nursing Library |
| 906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) |
|---|
| a |
7 |
| b |
cbc |
| c |
orignew |
| d |
2 |
| e |
epcn |
| f |
20 |
| g |
y-gencatlg |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
National Library of Medicine Classification |
| Koha item type |
General Book |
| 998 ## - STAFF NAME (NMU) |
|---|
| Cataloger |
nuch |
